Praxis der Surfactanttherapie

Einleitung

Seit der Erstbeschreibung der Surfactanttherapie durch Fujiwara 1980 [1] sind mehr als 30 Jahre vergangen. Die Zulassung von Surfactantpräparaten in Deutschland Anfang der 1990er Jahre führte zu einem deutlichen Rückgang u. a. der Beatmungsanwendung, der Mortalität und der Pneumothoraxrate. Die Surfactanttherapie ist mittlerweile aus dem klinischen Alltag in der Neonatologie nicht mehr wegzudenken.

• Literatur

• 1 Fujiwara T, Chida S, Watabe Y et al. Artificial surfactant therapy in hyaline-membrane disease. The Lancet 1980; 315: 55-59
• 2 Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane. AM J Dis Child 1959; 5: 517-523
• 3 Robillard E, Alarie Y, Dagenais-Perusse P et al. Microaerosol administration of synthetic beta-gamma-dipalmitolyl-l-alpha-lecitin in the respiratory distress syndrome: a preliminary report. Can Med Assoc J 1964; 90: 55-57
• 4 Halliday HL. Surfactants: past, present and future. J Perinatol 2008; 28: 47-56
• 5 Ramanathan R. Choosing a right surfactant for Respiratory Distress Syndrome treatment. Neonatology 2009; 95: 1-5
• 6 Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Chochrane Database Syst Rev 2001; DC000144
• 7 Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; CD004454
• 8 Herting E, Schiffmann H, Roth C et al. Surfactant lavage demonstrates protein fibrils in an neonate with congenital surfactant protein b deficiency. Am JRespir Crit Care Med 2002; 166: 1292-1294
• 9 Valls-i-Soler A, López-Herida J, Fernández-Ruanova MB et al. A simplified surfactant dosing procedure in respiratory distress syndrome: the “side-hole” randomized study. Spanish Surfactant Collaborative Group. Acta Paediatr 1997; 86: 747-751
• 10 Stevens TP, Harrington EW, Blennow M et al. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilaton for preterm infants with or at risk for respiratoiry distress syndrome. Cochrane Syst Rev 2007; CD003063
• 11 Verder H, Robertson B, Greisen G et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994; 331: 1051-1055
• 12 Bohlin K, Jonsson B, Gustafsson A-S et al. Continuous positive airway pressure and surfactant. Neonatology 2008; 93: 309-315
• 13 Kribs A, Pillekamp F, Hünseler C et al. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age ≤ 27 weeks). Paediatr Anaesth 2007; 17: 364-369
• 14 Kribs A, Härtel C, Kattner E et al. Spontaneous breathing in preterm infants with respiratory distress: first multi-center data. Klin Paediatr 2010; 222: 13-17
• 15 Goepel W, Kribs A, Ziegler A et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011; 378: 1627-1634
• 16 Herting E, Kribs A, Roth B et al. Intratracheal surfactant instillation using a thin diameter tube in spontaneously breathing infants – on the way to clinical practice in Germany?. Neonatology 2012; 101: 362 (Abstract)
• 17 Kribs A, Roll C, Göpel W et al. Eine endotracheale Surfactantgabe unter CPAP-unterstützter Spontanatmung optimiert das Outcome extrem unreifer Frühgeborener – Ergebnisse der NINSAPP-Studie (Non Intubated Surfactant Application). Monatsschr Kinderheilkd 2013; 161: 1, 23 (Abstract)
• 18 Dargaville PA. Innovation in surfactant therapy I: surfactant lavage and surfactant administration by fluid bolus using minimal invasive techniques. Neonatology 2012; 101: 326-336
• 19 Klebermass-Schrehof K, Wald M, Schwindt J et al. Less Invasive Surfactant Administration in Extremely Preterm Infants: Impact on Mortality and Morbidity. Neonatology 2013; 103: 252-258
• 20 Herting E, Kribs A, Roth B et al. Growth and development of VLBW-infants after less invasive surfactant administration during spontaneous breathing: two year follow-up of the AMV-trial. Neonatology 2013; 103: 349 (Abstract)
• 21 Kanmaz HG, Erdeve O, Canpolat FE et al. Surfactant Administration via Thin Catheter During Spontaneous Breathing: Randomized Controlled Trial. Pediatrics 2013; 131: e502-e509
• 22 Dargaville PA, Aiyappan A, De Paoli AG et al. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal 2013; 98: F122-126
• 23 Support Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010; 362: 1970-1979
• 24 Morley CJ, Davis PG, Doyle LW et al. COIN Trial Investigators. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008; 358: 700-708
• 25 Pillow JJ, Minocchieri S. Innovation in surfactant therapy II: surfactant administration by aerosolization. Neonatology 2012; 101: 337-344
• 26 Kattwinkel J, Robinson M, Bloom BT et al. Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol 2004; 24: 360-365
• 27 Sweet DG, Carnielli V, Greisen G et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants – 2013 update. Neonatology 2013; 103: 353-368
• 28 Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2012; CD000510
• 29 Gortner L, Herting E. Sufactanttherapie des Atemnotsyndroms Frühgeborener (RDS). AWMF-Leitlininien-Register 024/021
• 30 Ramanathan R, Rasmussen MR, Gerstmann DR et al. A randomized multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004; 21: 109-119
• 31 Speer CP, Robertson B, Curstedt T et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 1992; 89: 13-20
• 32 Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97: 48-52
• 33 Herting E, Gefeller O, Land M et al. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 2000; 106: 957-964
• 34 Pandit PB, Dunn MS, Kelly EN et al. Surfactant replacement in neonates with early chronic lung disease. Pediatrics 1995; 95: 851-854
• 35 Aziz A, Ohlsson A. Surfactant for pulmonary haemorrhage in neonates. Cochrane Database Syst Rev 2012; CD005254
• 36 Wiswell TE, Knight GR, Finer NN et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002; 109: 1081-1087
• 37 Herting E, Gan X, Rauprich P et al. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia. Am J Respir Crit Care Med 1999; 159: 1862-1867